Genital Neoplasm Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Genital Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 1Phase 2

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Prostate CancerMetastatic Castration-resistant Prostate CancerUrogenital Neoplasms+3 more
Blue Earth Therapeutics Ltd82 enrolled19 locationsNCT05413850
Recruiting

A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies

Urothelial CancerBladder CancerGenitourinary Cancer+2 more
National Cancer Institute (NCI)1,100 enrolled1 locationNCT04923178
Recruiting
Phase 1

Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

Urothelial CancerBladder CancerGenitourinary Cancer+2 more
National Cancer Institute (NCI)100 enrolled1 locationNCT04235777
Recruiting
Phase 2

CD70-targeted immunoPET Imaging of Kidney Cancer

NeoplasmsKidney NeoplasmsUrogenital Neoplasms+1 more
RenJi Hospital300 enrolled1 locationNCT06680089
Recruiting
Phase 2

Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer

Penile CancerUrogenital NeoplasmsPenile Squamous Cell Carcinoma+3 more
The Netherlands Cancer Institute27 enrolled2 locationsNCT06353906
Recruiting

Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma

CarcinomaCarcinoma, Renal CellNeoplasms+10 more
Jinling Hospital, China39 enrolled1 locationNCT06676527
Recruiting
Phase 1Phase 2

Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617

Prostate CancerNeoplasmsNeoplasms by Site+7 more
Pathos AI, Inc.252 enrolled10 locationsNCT06785636
Recruiting
Phase 2

Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab

NeoplasmsNeoplasms by SiteUrinary Bladder Neoplasm+8 more
The Netherlands Cancer Institute90 enrolled9 locationsNCT06237920
Recruiting
Phase 1Phase 2

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Advanced Solid TumorsCarcinomaNeoplasms+9 more
Marengo Therapeutics, Inc.365 enrolled32 locationsNCT05592626
Recruiting
Not Applicable

Research Project on Reminders and Self-Sampling Can Increase Participation in Gynecology Cell Sampling - Preventive Examination Against Cervical Cancer.

Cervical CancerNeoplasmsNeoplasms by Site+7 more
Karolinska Institutet20,000 enrolled6 locationsNCT04061967
Recruiting
Phase 4

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

NeoplasmsMetastatic Prostate CancerNeoplasms by Site+8 more
VA Greater Los Angeles Healthcare System15 enrolled1 locationNCT06706921
Recruiting
Phase 2

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Ovarian NeoplasmsUrogenital NeoplasmsCarcinoma, Ovarian Epithelial+5 more
Sheba Medical Center24 enrolled1 locationNCT04519151